Teva Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Teva Pharmaceuticals (Parsippany, NJ): 125 reconciled FDA prescription therapies (0.1% 2025 to 2030 cliff risk), $4.09B 2024 CMS Part D & Medicaid spend, and 137 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterParsippany, NJ
Reconciled FDA Portfolio Therapies125
2025 to 2030 Patent-Cliff Revenue Exposure0.1%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$4.09B
2024 Medicare Part D Spend$2.80B
2024 Medicaid Spend$1.29B
California HCAI SB 17 Filings137 WAC filings (max 125.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.